| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ANXA9 |
| Uniprot No | O76027 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 8-345aa |
| 氨基酸序列 | MAPSLTQEILSHLGLASKTAAWGTLGTLRTFLNFSVDKDAQRLLRAITGQGVDRSAIVDVLTNRSREQRQLISRNFQERTQQDLMKSLQAALSGNLERIVMALLQPTAQFDAQELRTALKASDSAVDVAIEILATRTPPQLQECLAVYKHNFQVEAVDDITSETSGILQDLLLALAKGGRDSYSGIIDYNLAEQDVQALQRAEGPSREETWVPVFTQRNPEHLIRVFDQYQRSTGQELEEAVQNRFHGDAQVALLGLASVIKNTPLYFADKLHQALQETEPNYQVLIRILISRCETDLLSIRAEFRKKFGKSLYSSLQDAVKGDCQSALLALCRAEDM |
| 预测分子量 | 53.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **标题**: "ANXA9 promotes colorectal cancer progression by regulating MYC expression"
**作者**: Li X, et al.
**摘要**: 研究利用重组ANXA9蛋白验证其在结直肠癌细胞中的促癌机制，证实其通过调控MYC信号通路增强肿瘤侵袭性。
2. **标题**: "Structural insights into ANXA9-lipid interactions by recombinant protein analysis"
**作者**: Wang Y, et al.
**摘要**: 通过大肠杆菌表达系统获得高纯度ANXA9重组蛋白，结合X射线晶体学揭示其与特定磷脂结合的分子结构基础。
3. **标题**: "ANXA9 as a biomarker in gastric cancer: Recombinant protein-based validation"
**作者**: Kim S, et al.
**摘要**: 利用哺乳动物细胞表达的重组ANXA9蛋白进行临床样本验证，发现其高表达与胃癌患者预后不良显著相关。
4. **标题**: "Recombinant ANXA9 modulates calcium signaling in breast cancer cells"
**作者**: Gonzalez R, et al.
**摘要**: 研究通过体外表达ANXA9重组蛋白，证明其通过调控钙离子内流影响乳腺癌细胞的迁移与凋亡抵抗。
---
注：上述文献信息为示例性内容，实际引用需根据具体文献调整。建议通过PubMed或Web of Science以“ANXA9 recombinant protein”为关键词检索最新研究。
ANXA9 (Annexin A9) is a member of the annexin protein family, characterized by calcium-dependent membrane-binding properties and diverse roles in cellular processes such as vesicle trafficking, cell proliferation, and apoptosis. Unlike other annexins, ANXA9 is less studied, but emerging evidence links it to oncogenic processes, particularly in gastrointestinal cancers. It is overexpressed in gastric, colorectal, and hepatocellular carcinomas, suggesting its potential as a diagnostic or prognostic biomarker. ANXA9 may influence tumor progression by modulating cell adhesion, signaling pathways, or drug resistance, though its exact mechanisms remain under investigation.
Recombinant ANXA9 protein is produced using genetic engineering techniques, typically by expressing the ANXA9 gene in bacterial (e.g., *E. coli*) or mammalian cell systems. This approach ensures high purity and specificity, enabling functional studies to dissect its biological roles. The recombinant protein retains calcium-binding capacity and structural motifs critical for membrane interaction, allowing researchers to explore its interactions with phospholipids, cytoskeletal components, or signaling molecules *in vitro*.
Applications of recombinant ANXA9 include elucidating its involvement in cancer biology, screening therapeutic agents targeting ANXA9-associated pathways, and developing antibodies for diagnostic assays. Its study also contributes to understanding annexin family evolution, as ANXA9 exhibits unique tissue-specific expression patterns compared to other annexins. Despite its underexplored status, ANXA9’s association with aggressive tumor phenotypes positions it as a promising subject for translational research, particularly in precision oncology and biomarker discovery. Further studies are needed to clarify its physiological functions and therapeutic potential.
×
